See more : Sotherly Hotels Inc. (SOHOB) Income Statement Analysis – Financial Results
Complete financial analysis of NuGen Medical Devices Inc. (NGMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NuGen Medical Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Svedbergs i Dalstorp AB (publ) (SVED-B.ST) Income Statement Analysis – Financial Results
- Aeon Co., Ltd. (8267.T) Income Statement Analysis – Financial Results
- Stroud Resources Ltd. (SDURF) Income Statement Analysis – Financial Results
- Toppan Inc. (7911.T) Income Statement Analysis – Financial Results
- Alpha Star Acquisition Corporation (ALSA) Income Statement Analysis – Financial Results
NuGen Medical Devices Inc. (NGMDF)
About NuGen Medical Devices Inc.
NuGen Medical Devices Inc., a specialty medical device company, focuses on developing and commercializing novel drug delivery technologies. It offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, and psoriasis, as well as DNA and conventional/pediatric vaccines. The company was formerly known as BuzBuz Capital Corp. NuGen Medical Devices Inc. is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 331.40K | 152.36K | 137.65K | 47.30K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 166.56K | 705.59K | 45.42K | 12.91K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 164.84K | -553.23K | 92.22K | 34.39K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 49.74% | -363.11% | 67.00% | 72.70% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.52M | 4.24M | 1.72M | 0.00 | 995.65K | 603.33K | 415.77K |
| Selling & Marketing | 0.00 | 0.00 | 6.05M | 2.65M | 478.44K | 582.57K | 98.78K |
| SG&A | 7.52M | 4.24M | 7.76M | 2.65M | 132.14K | 1.66M | 608.03K |
| Other Expenses | 690.84K | 57.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.21M | 4.24M | 7.76M | 2.65M | 132.14K | 1.65M | 610.57K |
| Cost & Expenses | 8.38M | 4.95M | 7.81M | 2.66M | 132.14K | 1.65M | 610.57K |
| Interest Income | 0.00 | 150.91K | 20.00K | 22.85K | 0.00 | 136.87K | 104.42K |
| Interest Expense | 1.24M | 1.01M | 1.22M | 672.19K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 690.84K | 652.40K | 626.94K | 387.78K | 1.20K | 1.29K | 1.76K |
| EBITDA | -7.40M | -4.14M | -5.17M | -2.22M | -132.14K | -1.66M | -608.03K |
| EBITDA Ratio | -2,233.32% | -2,718.36% | -4,979.77% | -5,135.51% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.05M | -4.79M | -7.67M | -2.61M | -132.14K | -1.66M | -609.79K |
| Operating Income Ratio | -2,428.48% | -3,146.56% | -5,573.13% | -5,521.05% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.28M | -780.71K | -1.31M | -1.05M | -24.20K | -129.70K | -105.20K |
| Income Before Tax | -9.33M | -5.57M | -7.10M | -3.66M | -156.34K | -1.79M | -714.98K |
| Income Before Tax Ratio | -2,814.83% | -3,658.98% | -5,161.08% | -7,734.93% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 33.80K | 3.18K | 2.96K | 12.17K | -1.20K | 0.00 | 0.00 |
| Net Income | -9.36M | -5.58M | -7.11M | -3.67M | -156.34K | -1.79M | -714.98K |
| Net Income Ratio | -2,825.02% | -3,661.07% | -5,163.23% | -7,760.66% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.06 | -0.10 | -0.14 | -0.03 | -0.09 | -0.07 |
| EPS Diluted | -0.06 | -0.06 | -0.10 | -0.14 | -0.03 | -0.09 | -0.07 |
| Weighted Avg Shares Out | 167.66M | 90.10M | 68.67M | 27.05M | 4.75M | 19.65M | 9.70M |
| Weighted Avg Shares Out (Dil) | 167.66M | 90.10M | 68.67M | 27.05M | 4.75M | 19.65M | 9.70M |
NuGen Announces Completion of InsuJet(TM) Training with Sol-Millennium(TM) Brazil
Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of June 26, 2024, the commercial...
NuGen Announces Repeat Order for Growing InsuJet(TM) Demand in Yemen
Toronto, Ontario--(Newsfile Corp. - June 28, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that Rosheta for Medicines and Medical Supplies ("Rosheta"),...
NuGen Announces Initial Purchase Order from Sol-Millennium(TM) for Pharmacy Launches in the Canadian and European Markets
Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices for the subcutaneous administration of therapeutics, is pleased to announce that Sol-MillenniumTM Medical Inc. ("Sol-M") has...
NuGen Announces Release of Financial Results for Q1 2024 & Updates on Strong Commercial Momentum in Q2
Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, announces the release Q1 2024 Financial Results and is pleased to provide...
NuGen Announces Debt Settlement and Amendments to Care4Pharma Share Purchase Agreement
Toronto, Ontario--(Newsfile Corp. - April 15, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") announces that it has agreed to settle an aggregate of €275,000 of indebtedness owed to Care4Pharma B.V. ("Care4Pharma"), an arm's length creditor...
NuGen Announces Completion of Product Training with Sol Millennium as European Markets Expand
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of January 30th, 2024, Sol-Millennium Medical...
NuGen Receives Two Additional Sales Orders for InsuJet(TM) and Expands Distribution into Argentina, Chile, Costa Rica and Peru
Toronto, Ontario--(Newsfile Corp. - January 19, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to report that its distribution partner in Mexico, Science-Link Trading...
NuGen Medical Signs 5-year Distribution Agreement for InsuJet(TM) with Verrue Consulting Group in Belgium
Toronto, Ontario--(Newsfile Corp. - December 19, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of December 17, 2023, Verrue Consulting...
NuGen Medical Signs 5-Year Distribution Agreement for InsuJet(TM) with Advance Medical Life Co.
Toronto, Ontario--(Newsfile Corp. - December 14, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that, as of December 12, 2023, Advance Medical...
Diabetic Lifestyle Subscription Business Launched on Shopify as NuGen's B2C Business Vertical
www.insujet.com - a diabetic e-commerce store Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce the official...
Source: https://incomestatements.info
Category: Stock Reports